BIOTE CORP -A (BTMD) Fundamental Analysis & Valuation

NASDAQ:BTMD • US0906831039

Current stock price

1.53 USD
+0.09 (+6.25%)
At close:
1.53 USD
0 (0%)
After Hours:

This BTMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. BTMD Profitability Analysis

1.1 Basic Checks

  • BTMD had positive earnings in the past year.
  • BTMD had a positive operating cash flow in the past year.
  • BTMD had positive earnings in 4 of the past 5 years.
  • Of the past 5 years BTMD 4 years had a positive operating cash flow.
BTMD Yearly Net Income VS EBIT VS OCF VS FCFBTMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 25.13%, BTMD belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
  • BTMD has a better Return On Invested Capital (44.85%) than 99.48% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BTMD is significantly above the industry average of 12.98%.
  • The 3 year average ROIC (32.37%) for BTMD is below the current ROIC(44.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROIC 44.85%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
BTMD Yearly ROA, ROE, ROICBTMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 200 400 600

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.07%, BTMD belongs to the top of the industry, outperforming 87.56% of the companies in the same industry.
  • BTMD's Profit Margin has declined in the last couple of years.
  • BTMD has a Operating Margin of 18.50%. This is amongst the best in the industry. BTMD outperforms 86.53% of its industry peers.
  • BTMD's Operating Margin has declined in the last couple of years.
  • BTMD's Gross Margin of 71.46% is fine compared to the rest of the industry. BTMD outperforms 79.27% of its industry peers.
  • BTMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
BTMD Yearly Profit, Operating, Gross MarginsBTMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BTMD Health Analysis

2.1 Basic Checks

  • BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for BTMD has been increased compared to 1 year ago.
  • The number of shares outstanding for BTMD has been increased compared to 5 years ago.
  • The debt/assets ratio for BTMD has been reduced compared to a year ago.
BTMD Yearly Shares OutstandingBTMD Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M
BTMD Yearly Total Debt VS Total AssetsBTMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • BTMD has an Altman-Z score of 2.56. This is not the best score and indicates that BTMD is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.56, BTMD is doing good in the industry, outperforming 67.88% of the companies in the same industry.
  • BTMD has a debt to FCF ratio of 4.43. This is a neutral value as BTMD would need 4.43 years to pay back of all of its debts.
  • BTMD's Debt to FCF ratio of 4.43 is amongst the best of the industry. BTMD outperforms 84.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Altman-Z 2.56
ROIC/WACC5.96
WACC7.52%
BTMD Yearly LT Debt VS Equity VS FCFBTMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M

2.3 Liquidity

  • BTMD has a Current Ratio of 1.22. This is a normal value and indicates that BTMD is financially healthy and should not expect problems in meeting its short term obligations.
  • BTMD has a Current ratio of 1.22. This is in the lower half of the industry: BTMD underperforms 77.72% of its industry peers.
  • BTMD has a Quick Ratio of 1.22. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BTMD's Quick ratio of 0.79 is on the low side compared to the rest of the industry. BTMD is outperformed by 82.38% of its industry peers.
Industry RankSector Rank
Current Ratio 1.22
Quick Ratio 0.79
BTMD Yearly Current Assets VS Current LiabilitesBTMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. BTMD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 277.27% over the past year.
  • Measured over the past years, BTMD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -26.76% on average per year.
  • Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -21.22% in the last year.
  • BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.51% yearly.
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%

3.2 Future

  • Based on estimates for the next years, BTMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.65% on average per year.
  • The Revenue is expected to grow by 8.86% on average over the next years. This is quite good.
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BTMD Yearly Revenue VS EstimatesBTMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
BTMD Yearly EPS VS EstimatesBTMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

8

4. BTMD Valuation Analysis

4.1 Price/Earnings Ratio

  • BTMD is valuated cheaply with a Price/Earnings ratio of 1.84.
  • Based on the Price/Earnings ratio, BTMD is valued cheaply inside the industry as 98.45% of the companies are valued more expensively.
  • BTMD is valuated cheaply when we compare the Price/Earnings ratio to 25.23, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 6.00, which indicates a rather cheap valuation of BTMD.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BTMD indicates a rather cheap valuation: BTMD is cheaper than 93.26% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of BTMD to the average of the S&P500 Index (23.28), we can say BTMD is valued rather cheaply.
Industry RankSector Rank
PE 1.84
Fwd PE 6
BTMD Price Earnings VS Forward Price EarningsBTMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 97.41% of the companies are valued more expensively.
  • 98.96% of the companies in the same industry are more expensive than BTMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 2.14
EV/EBITDA 4.13
BTMD Per share dataBTMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.34%
EPS Next 3Y11.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BTMD Dividend Analysis

5.1 Amount

  • BTMD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BTMD Fundamentals: All Metrics, Ratios and Statistics

BIOTE CORP -A

NASDAQ:BTMD (3/20/2026, 8:00:02 PM)

After market: 1.53 0 (0%)

1.53

+0.09 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)05-05
Inst Owners63.61%
Inst Owner Change0.4%
Ins Owners10.06%
Ins Owner Change0%
Market Cap60.51M
Revenue(TTM)192.22M
Net Income(TTM)27.05M
Analysts81.82
Price Target4.94 (222.88%)
Short Float %5.15%
Short Ratio7.82
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)189.9%
Min EPS beat(2)17.65%
Max EPS beat(2)362.15%
EPS beat(4)4
Avg EPS beat(4)254.13%
Min EPS beat(4)17.65%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)90.98%
EPS beat(12)7
Avg EPS beat(12)15.74%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.53%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.5%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.59%
Revenue beat(12)4
Avg Revenue beat(12)-1.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.91%
EPS NQ rev (1m)-13.64%
EPS NQ rev (3m)-13.64%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.6%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-3.12%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)-2.41%
Valuation
Industry RankSector Rank
PE 1.84
Fwd PE 6
P/S 0.31
P/FCF 2.14
P/OCF 1.72
P/B N/A
P/tB N/A
EV/EBITDA 4.13
EPS(TTM)0.83
EY54.25%
EPS(NY)0.26
Fwd EY16.67%
FCF(TTM)0.72
FCFY46.82%
OCF(TTM)0.89
OCFY58.16%
SpS4.86
BVpS-1.48
TBVpS-1.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 25.13%
ROE N/A
ROCE 56.77%
ROIC 44.85%
ROICexc 72.95%
ROICexgc 117.64%
OM 18.5%
PM (TTM) 14.07%
GM 71.46%
FCFM 14.74%
ROA(3y)9.95%
ROA(5y)17.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)32.37%
ROIC(5y)N/A
ROICexc(3y)67.85%
ROICexc(5y)N/A
ROICexgc(3y)109.57%
ROICexgc(5y)N/A
ROCE(3y)40.97%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.74%
ROICexc growth 3YN/A
ROICexc growth 5Y-35.99%
OM growth 3YN/A
OM growth 5Y-7.47%
PM growth 3YN/A
PM growth 5Y-10.89%
GM growth 3Y2.22%
GM growth 5Y3.08%
F-Score7
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.43
Debt/EBITDA 2.57
Cap/Depr 187.03%
Cap/Sales 3.57%
Interest Coverage 4.51
Cash Conversion 89.73%
Profit Quality 104.75%
Current Ratio 1.22
Quick Ratio 0.79
Altman-Z 2.56
F-Score7
WACC7.52%
ROIC/WACC5.96
Cap/Depr(3y)157.42%
Cap/Depr(5y)165.61%
Cap/Sales(3y)2.85%
Cap/Sales(5y)2.48%
Profit Quality(3y)682.14%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)277.27%
EPS 3YN/A
EPS 5Y-26.76%
EPS Q2Q%-40%
EPS Next Y-69.28%
EPS Next 2Y-41.34%
EPS Next 3Y11.89%
EPS Next 5Y9.65%
Revenue 1Y (TTM)-21.22%
Revenue growth 3Y5.22%
Revenue growth 5Y10.51%
Sales Q2Q%-6.87%
Revenue Next Year0.32%
Revenue Next 2Y3.4%
Revenue Next 3Y4.7%
Revenue Next 5Y8.86%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5Y2.26%
EBIT Next Year51.43%
EBIT Next 3Y25.51%
EBIT Next 5Y17.45%
FCF growth 1Y-26.01%
FCF growth 3YN/A
FCF growth 5Y2.5%
OCF growth 1Y-22.21%
OCF growth 3YN/A
OCF growth 5Y5.89%

BIOTE CORP -A / BTMD Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for BIOTE CORP -A?

ChartMill assigns a fundamental rating of 6 / 10 to BTMD.


Can you provide the valuation status for BIOTE CORP -A?

ChartMill assigns a valuation rating of 8 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.


Can you provide the profitability details for BIOTE CORP -A?

BIOTE CORP -A (BTMD) has a profitability rating of 7 / 10.


How financially healthy is BIOTE CORP -A?

The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.


How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?

The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.